NYSE · EW

Edwards Lifesciences Corp.

$83.80 +$1.17 (+1.42%) 1D Market open
Session Pulse Regular session 1 mentions on Mon 1 SEC filing since Mon close 4 its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$47.58B
Market cap
43.40×
P/E · TTM
$6.30B
Revenue · TTM
$1.10B
Net income
EPS · TTM $1.86
Dividend yield —
Free cash flow $1.09B
Beta · 1Y 0.57
EBITDA · TTM $1.46B
Gross margin 77.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    An insider transaction hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4, TIMESTAMPED
  • Jul 23
    A material event was filed (Form 8-K).

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$47.58B
Enterprise value$44.22B
Shares outstanding575.8M
52-wk range$72.30 – $96.29
Avg volume · 20D3.8M
Net cash $3.36B
Book value / share$17.57
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNYSE
About Edwards Lifesciences Corp.
IPO dateApr 3, 2000
Employees16000

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E43.40
P/S7.55
P/FCF43.67
EV/EBITDA30.31
EV/Sales7.02
Graham №$27.15

Profitability

Gross 77.9%
Operating 20.6%
Net 17.4%
FCF 17.3%
ROE / ROIC 10.8% · 14.8%

Financial Health

Current ratio4.42
Quick ratio3.63
Debt / equity0.06
Debt / EBITDA 0.41Low leverage
Net cash $3.36B
Working capital$4.82B

Cash Flow · TTM

Operating CF $1.36B
Capex −$269.10M
Free cash flow $1.09B
Buybacks $1.06B
Dividends paid —
Shareholder yield 2.2%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

12.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$27.15 vs $83.04
Trades 3.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings